Adds an additional commercial and strategic rare disease product to Eton’s portfolio Galzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill. , Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq:
